Extract
Cardiovascular (CV) diseases and lower respiratory tract infections dominate human burden of disease across the world. Combined, they cause nearly 20 million or 36% of annual global deaths [1]. Additionally, both are linked together and interact bidirectionally: underlying CV disease is an established risk factor for the development of pneumonia and poor prognosis during pneumonia [2, 3], and vice versa, the role of pneumonia as risk factor for CV complications and new-onset CV disease has been demonstrated [4–6].
Abstract
Preventing cardiovascular events after pneumonia by aspirin: another step forward, but questions remain https://bit.ly/2H5z4OB
Footnotes
Conflict of interest: M. Kolditz has nothing to disclose.
Conflict of interest: T. Welte reports grants from the German Ministry of Research and Education (BMBF), outside the submitted work.
- Received October 8, 2020.
- Accepted October 10, 2020.
- Copyright ©ERS 2021